ClinicalTrials.gg
RecruitingNCT05338619PLATINUMUpdated Sep 1, 2023

A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

A Phase 2 interventional study of Lazertinib in Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer and Non-squamous Non-small-cell Lung Cancer, sponsored by Sung Yong Lee. Recruiting at 13 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-01.

Sponsored by Sung Yong Lee · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Jun 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung — 6 open to participants now, 11 under way, 2 of them phase 3. lazertinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
9th of 20
77 · median 67
Started
2022
with 3 others
Phase 2
12 of 20
6 open now
Primary completion
2026-03
later than 5 of 10 live
Registered
11th of 20
by date
Lead sponsor
1 of 20
Sung Yong Lee

Among the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by planned enrollment, is one of 4 that started in 2022, is one of 12 in phase 2, reaches primary completion later than 5 of the 10 other live ones, and was the 11th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About lazertinib

lazertinib: first FDA approval 2024 (LAZCLUZE), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The "PACIFIC" trial confirmed that the consolidation therapy with durvalumab in patients with stage III, locally advanced, unresectable NSCLC that had not progressed after definitive platinum-based chemoradiation therapy improved the progression-free survival (PFS) by about 17 months. However, in PACIFIC, no significant differences between durvalumab and placebo were observed in PFS. Unmet need remains in development of successful consolidation therapy following chemoradiation therapy in patients with EGFR-mutant stage III unresectable NSCLC.

A recent "ADAURA" study showed that Osimertinib as an adjuvant therapy after surgery significantly prolonged disease-free survival in EGFR mutation-positive patients. Lazertinib, like Osimertinib, is a third-generation EGFR TKI agent and has shown excellent anticancer effects in preclinical studies and in early clinical settings. Based on these results of the 3rd generation EGFR TKI, Lazertinib, it is expected that there is a clinical benefit Lazertinib as consolidation therapy.

This study aims to investigate the clinical benefits of Lazertinib (Trade name: LECLAZA Tab) consolidation therapy for patients with EGFR mutation-positive, unresectable stage III NSCLC after definitive platinum-based chemoradiation therapy.

Read the detailed description

This study is designed as a prospective, open-label, single-arm, multicenter, phase II, investigator-initiated trial. A total of 77 patients will participate in the study who have undergone definitive platinum-based concurrent chemoradiation therapy and have no disease progression. Patients are to be enrolled within 1 to 42 days after concurrent chemoradiation therapy and to be administrated with lazertinib 240mg oral once daily until disease progression, or unacceptable toxicity. Patients will visit every 8 weeks and perform CT/MRI tumor evaluation by investigator, and will be followed up for survival every 3 months by phone thereafter. Patients will be followed up till maximum of appropriately 4 years of which 3 years since the last patient enrollment must be.

03

Conditions studied

  • Non-small Cell Lung Cancer Stage III
  • EGFR Positive Non-small Cell Lung Cancer
  • Non-squamous Non-small-cell Lung Cancer

Keywords

  • NSCLC
  • Non-squamous cell carcinoma
  • EGFR
  • EGFR-TKI
  • Lazertinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years and older
  2. and cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) non-squamous cell carcinoma who present with locally advanced, unresectable, Stage III disease
  3. PS 0,1
  4. Expected of 6 months and more
  5. Patients who have received at least 2 cycles of definitive platinum-based concurrent chemoradiation therapy (CCRT) and who must be within 1 to 42 days after completion of radiation therapy
  6. Patients must not have had disease progression during or following CCRT
  7. Patients with adequate organ and bone marrow function
  8. Patients who give in written consent voluntarily to participate in this study

Exclusion criteria

Exclusion Criteria:

  1. History of interstitial lung disease, drug-induced interstitial lung disease, or radiation interstitial pneumonia
  2. History of other primary
  3. Mixed small cell and NSCLC histology
  4. Prior treatment with EGFR-TKI Therapy
  5. Unresolved toxicity of grade 2 or higher following chemoradiation
  6. Current history of CTCAE grade 2 or higher pneumonia prior to chemoradiation therapy
  7. Patients with severe to active ingredient or of the medicinal product
  8. Pregnant or breastfeeding patients
  9. Patients who do not agree to with medically acceptable method for at least 6 months after the end of study intervention treatment
  10. Patients who participated in clinical trials within 4 weeks before participating in this study
  11. Judgment by the investigator that the patient is unsuitable to participate in this study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
77 participants (estimated)

Study arms

  • Experimental
    Lazertinib

    Lazertinib 240mg, oral, QD

    Drug: Lazertinib

Interventions

  • Lazertinib 240mg (3 Tabs as Laclaza Tab 80mg) once daily in oral can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.

    Also known as: LECLAZA

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    The time from the date of enrollment until the date of disease progression or death (by any cause in the absence of progression) Per RECIST 1.1 as assessed by Investigator.

    Time frame: Tumor scan will be performed at baseline the every 8 weeks until confirmed disease progression (up to 4 years)

Secondary outcomes

  1. Overall survival (OS)

    The time from the date of enrollment until the date of death

    Time frame: Until death (up to maximum of approximately 4 years)

  2. Objective response rate (ORR)

    The number (%) of patient at least 1 visit response of Complete response (CR) or Partial response (PR). Per RECIST 1.1 as assessed by Investigator.

    Time frame: Tumor scan will be performed at baseline the every 8 weeks until confirmed disease progression (up to 4 years)

  3. Duration of response (DoR) Duration of response (DoR)

    The time from the date of first documented response until the first date of documented progression (or death in the absence of disease progression) Per RECIST 1.1 as assessed by Investigator.

    Time frame: Tumor scan will be performed at baseline the every 8 weeks until confirmed disease progression (up to 4 years)

  4. Time to death or distant metastasis (TTDM)

    The time from the date of enrollment until the first date of distant metastasis or death in the absence of distant metastasis. Per RECIST 1.1 as assessed by Investigator.

    Time frame: Until death or distant metastasis (up to maximum of approximately 4 years)

  5. Safety profile : Adverse Events according to CTCAE V5.0

    Adverse events, Serious adverse events or other significant safety findings

    Time frame: every visit (up to maximum of approximately 4 years)

Other outcomes

  1. Changes form baseline in different biomarkers

    Biomarker evaluations include tumor-educated platelets (TFP), circulating tumor DNA(ctDNA), and peripheral blood mononuclear cells (PMBCs). It will be investigated to understand the better and long-term survival, drug-resistant mechanism and hematology in occurrence of pneumonitis.

    Time frame: Pre-dose(within 6 week of completion of CCRT), after 8-week dosing, and confirmed disease progression (approximately 15 months)

07

Study locations

13 of 13 sites recruiting
  • Kosin University Gospel Hospital
    Busan, Korea, Republic of
    Recruiting
    • Jang · Contact82 51 990 6637
    • Tae Won Jang, MD, PhD · Principal investigator
  • Keimyung University Dongsan Hospital
    Daegu, Korea, Republic of
    Recruiting
    • Park · Contact82 53 258 4519
    • Sun Hyo Park, MD, PhD · Principal investigator
  • Kyungpook National University Medical Center
    Daegu, Korea, Republic of
    Recruiting
    • Shin Yup Lee, MD, PhD · Contact82 53 200 3091
  • Chungnam National University Hospital
    Daejeon, Korea, Republic of
    Recruiting
    • Lee · Contact82 42 280 6135
    • Jeong Eun Lee, MD, PhD · Principal investigator
  • Chonnam National University Hospital Hwasun Hospital
    Gwangju, Korea, Republic of
    Recruiting
    • Oh · Contact82 61 379 7869
    • In-Jae Oh, MD, PhD · Principal investigator
  • Inha University Hospital
    Incheon, Korea, Republic of
    Recruiting
    • Lim · Contact82 32 890 3894
    • Jun Hyeok Lim, MD, MS · Principal investigator
  • Pusan National University Yangsan Hospital
    Pusan, Korea, Republic of
    Recruiting
    • Seong Hoon Yoon, MD, PhD · Contact82 55 360 1415
  • Asan Medical Center
    Seoul, Korea, Republic of
    Recruiting
    • Choi · Contact82 2 3010 8358
    • Chang-Min Choi, MD, PhD · Principal investigator
  • Hanyang University Seoul Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Park · Contact82 2 2290 9065
    • Dong Won Park, MD, PhD · Principal investigator
  • Koera University Guro Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Lee · Contact82 2 2626 1914
    • Sung Yong Lee, MD, PhD · Principal investigator
    • Juwhan Choi, MD, PhD · Sub investigator
  • Korea University Anam Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Su In Choi, MD, PhD · Contact82 2 920 5439
  • Kyung Hee University Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Lee · Contact82 2 958 8511
    • Seung Hyeun Lee, MD, PhD · Principal investigator
  • Yonsei University Health System, Severance Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Kim · Contact82 2228 2268
    • Eunyoung Kim, MD, PhD · Principal investigator
08

References and documents

Publications

  • Choi J, Lee JE, Choi CM, Oh IJ, Lee KY, Jang TW, Lee SH, Kim EY, Park DW, Park SH, Lee SY. A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial). Thorac Cancer. 2022 Dec;13(23):3431-3435. doi: 10.1111/1759-7714.14663. Epub 2022 Oct 19. PubMed 36259253 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Mar 2026, 44 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 44 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2022
First posted
Apr 21, 2022
StartActual
Jun 30, 2022
Primary completionEst.
Mar 2, 2026
CompletionEst.
Mar 2, 2026
Last update
Sep 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05338619
Lead sponsor
Sung Yong Lee
Collaborators
Yuhan Corporation
Responsible party
Sung Yong Lee (Professor, Korea University Guro Hospital) — Sponsor-investigator
First posted
Apr 21, 2022
Start date
Jun 30, 2022
Primary completion
Mar 2, 2026 (estimated)
Completion
Mar 2, 2026 (estimated)
Last update
Sep 1, 2023

Study contacts

Sung Yong Lee
Contact
syl0801@korea.ac.kr
82 2 2626 1914
Youngsun Cho
Contact
choyoungsun@procuratio.kr
82 70 4820 0249
Sung Yong Lee, MD, PhD
principal investigator · Korea University Guro Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lazertinib

Start the discussion